Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2-targeting biologics such as anti-IgE, anti-IL4Rα, anti-IL5, and anti-IL5Rα have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma.

Department of Biomedical Science Humanitas University Pieve Emanuele Italy

Department of Clinical Pharmacy and Pharmacology and Department of General Practice UMCG and QPS NL Groningen The Netherlands

Department of Microbiology Immunology and Transplantation Allergy and Clinical Immunology Research Group Leuven Belgium

Department of Otolaryngology Head and Neck Surgery Eastern Virginia Medical School Norfolk Virginia

Department of Otorhinolaryngology Amsterdam University Medical Centres Location AMC Amsterdam Amsterdam The Netherlands

Department of Otorhinolaryngology Head and Neck Surgery University Hospitals Leuven Leuven Belgium

Department of Otorhinolaryngology Hospital Clínic Universitat de Barcelona IDIBAPS CIBERES Barcelona Catalonia Spain

Department of Respiratory Disease University Hospital Arnaud de Villeneuve Montpellier France

Department of Respiratory Medicine 1st Faculty of Medicine Charles University and Thomayer Hospital Prague Czech Republic

Department of Respiratory Medicine and Allergology Lund University Lund Sweden

Department of Respiratory Medicine Ghent University Hospital Gent Belgium

Division of ENT Diseases CLINTEC Karolinska Institute and Department of ENT Diseases Karolinska University Hospital Stockholm Sweden

Division of Otolaryngology Head and Neck Surgery University of Montreal Hospital Centre Montreal Quebec Canada

Division of Rhinology Allergy and Endoscopic Skull Base Surgery University of North Carolina at Chapel Hill Chapel Hill North Carolina

Division of Sinonasal Disorders and Allergy Department of Otolaryngology Head and Neck Surgery University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA

ENT Department University Hospital of Nancy Brabois ILM Nancy France

European Forum for Research and Education in Allergy and Airway Diseases Brussels Belgium

Guy's and St Thomas' NHS Foundation Trust London UK

Opuscomms London UK

Personalized Medicine Asthma and Allergy Humanitas Clinical and Research Center IRCCS Rozzano Italy

Rhinology and Endoscopic Skull Base Surgery UCLA Department of Head and Neck Surgery Los Angeles California

Royal National Throat Nose and Ear Hospital University College London Hospitals London UK

Upper Airways Research Laboratory University of Ghent Gent Belgium

See more in PubMed

Hastan D, Fokkens WJ, Bachert C, et al. Chronic rhinosinusitis in Europe–an underestimated disease. A GA2LEN study. Allergy. 2011;66(9):1216‐1223. PubMed

Hirsch AG, Stewart WF, Sundaresan AS, et al. Nasal and sinus symptoms and chronic rhinosinusitis in a population‐based sample. Allergy. 2017;72(2):274‐281. PubMed PMC

Ostovar A, Fokkens WJ, Vahdat K, Raeisi A, Mallahzadeh A, Farrokhi S. Epidemiology of chronic rhinosinusitis in Bushehr, southwestern region of Iran: a GA2LEN study. Rhinology. 2018;57(1):43‐48. PubMed

Shi JB, Fu QL, Zhang H, et al. Epidemiology of chronic rhinosinusitis: results from a cross‐sectional survey in seven Chinese cities. Allergy. 2015;70(5):533‐539. PubMed PMC

Fokkens WJ, Lund VJ, Mullol J et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl. 2012;23:3 p preceding table of contents, 1‐298. PubMed

Dietz de Loos D, Lourijsen ES, Wildeman M, et al. Prevalence of chronic rhinosinusitis in the general population based on sinus radiology and symptomatology. J Allergy Clin Immunol. 2019;143(3):1207‐1214. PubMed

Tomassen P, Newson RB, Hoffmans R, et al. Reliability of EP3OS symptom criteria and nasal endoscopy in the assessment of chronic rhinosinusitis–a GA(2) LEN study. Allergy. 2011;66(4):556‐561. PubMed

Khan A, Vandeplas G, Huynh T, et al. The global allergy and asthma European network (GALEN rhinosinusitis cohort: a large European cross‐sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology. 2019;57(1):32‐42. PubMed

Kowalski ML, Agache I, Bavbek S et al. Diagnosis and management of NSAID‐exacerbated respiratory disease (N‐ERD)‐a EAACI position paper. Allergy. 2019;74(1):28‐39. PubMed

Philpott CM, Erskine S, Hopkins C, et al. Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. Respir Res. 2018;19(1):129. PubMed PMC

Wu D, Bleier BS, Li L, et al. Clinical phenotypes of nasal polyps and comorbid asthma based on cluster analysis of disease history. J Allergy Clin Immunol Pract. 2018;6(4):1297‐305.e1. PubMed

Liao B, Liu J‐X, Li Z‐Y, et al. Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes. Allergy 2018;73(7):1459‐1469. PubMed PMC

Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449‐1456.e4. PubMed

Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45‐53. PubMed PMC

Lin DC, Chandra RK, Tan BK, et al. Association between severity of asthma and degree of chronic rhinosinusitis. Am J Rhinol Allergy. 2011;25(4):205‐208. PubMed PMC

Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U‐BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46(5):1308‐1321. PubMed

Zhang Y, Derycke L, Holtappels G, et al. Th2 cytokines orchestrate the secretion of MUC5AC and MUC5B in IL‐5‐positive chronic rhinosinusitis with nasal polyps. Allergy. 2019;74(1):131‐140. PubMed

De Greve G, Hellings PW, Fokkens WJ, Pugin B, Steelant B, Seys SF. Endotype‐driven treatment in chronic upper airway diseases. Clin Transl Allergy. 2017;7:22. PubMed PMC

Seys SF, Scheers H, Van den Brande P, et al. Cluster analysis of sputum cytokine‐high profiles reveals diversity in T(h)2‐high asthma patients. Respir Res 2017;18(1):39. PubMed PMC

Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002;57(10):875‐879. PubMed PMC

Orlandi RR, Kingdom TT, Hwang PH, et al. International consensus statement on allergy and rhinology: rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(Suppl 1):S22‐209. PubMed

Pedersen SE, Bateman ED, Boulet L‐P et al. e. 2018 GINA report, global strategy for Asthma management and prevention. https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-tracked_v1.3.pdf;2018://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-tracked_v1.3.pdf;2018 PubMed

Pundir V, Pundir J, Lancaster G, et al. Role of corticosteroids in functional endoscopic Sinus surgery–a systematic review and meta‐analysis. Rhinology. 2016;54(1):3‐19. PubMed

Voorham J, Xu X, Price DB, et al. Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. Allergy. 2019;74(2):273‐283. PubMed PMC

Rudmik L, Soler ZM, Hopkins C, et al. Defining appropriateness criteria for endoscopic sinus surgery during management of uncomplicated adult chronic rhinosinusitis: a RAND/UCLA appropriateness study. Rhinology. 2016;54(2):117‐128. PubMed

Hopkins C, Surda P, Bast F, Hettige R, Walker A, Hellings PW. Prevention of chronic rhinosinusitis. Rhinology. 2018;56(4):307‐315. PubMed

Kilty SJ, Lasso A, Mfuna‐Endam L, Desrosiers MY. Case‐control study of endoscopic polypectomy in clinic (EPIC) versus endoscopic sinus surgery for chronic rhinosinusitis with polyps. Rhinology. 2018;56(2):155‐157. PubMed

Yii A, Tay TR, Choo XN, Koh M, Tee A, Wang DY. Precision medicine in united airways disease: A "treatable traits" approach. Allergy. 2018;73(10):1964‐1978. PubMed

Tay TR, Hew M. Comorbid, "treatable traits" in difficult asthma: Current evidence and clinical evaluation. Allergy. 2018;73(7):1369‐1382. PubMed

Fokkens WJ, Reitsma S. Proposal for an algorithm on the management of chronic rhinosinusitis. Allergy. 2019;74 (in press). PubMed

Busse WW, Anti‐immunoglobulin E. (omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med. 2001;164(8 Pt 2):S12‐S17. PubMed

Asero R. Efficacy of omalizumab 150 mg/month as a maintenance dose in patients with severe chronic spontaneous urticaria showing a prompt and complete response to the drug. Allergy. 2018;73(11):2242‐2244. PubMed

Cugno M, Asero R, Ferrucci S, et al. Elevated IgE to tissue factor and thyroglobulin are abated by omalizumab in chronic spontaneous urticaria. Allergy. 2018;73(12):2408‐2411. PubMed

Ertas R, Ozyurt K, Atasoy M, Hawro T, Maurer M. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy. 2018;73(3):705‐712. PubMed

Kaplan AP, Gimenez‐Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017;72(4):519‐533. PubMed PMC

Hassani M, Koenderman L. Immunological and hematological effects of IL‐5(Ralpha) targeted therapy: an overview. Allergy. 2018;73(10):1979‐1988. PubMed PMC

Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate‐to‐severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486‐2496. PubMed

Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti‐IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:CD010834. PubMed PMC

Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid‐dependent severe asthma. N Engl J Med. 2018;378(26):2475‐2485. PubMed

Diamant Z, Vijverberg SJ, Agache I, et al. Much ado about Biologicals: highlights of the master class on biologicals, Prague, 2018. Allergy. 2019;74(4):837‐840. PubMed

Diamant Z, Vijverberg S, Alving K, et al. Towards clinically applicable biomarkers for asthma ‐ An EAACI position paper. Allergy. 2019. (in press). PubMed

Simpson EL, Bieber T, Guttman‐Yassky E, et al. Two phase 3 trials of Dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335‐2348. PubMed

Blauvelt A, de Bruin‐Weller M, Gooderham M, et al. Long‐term management of moderate‐to‐severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1‐year, randomised, double‐blinded, placebo‐controlled, phase 3 trial. Lancet. 2017;389(10086):2287‐2303. PubMed

Weller K, Ohanyan T, Hawro T, et al. Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab. Allergy. 2018;73(12):2406‐2408. PubMed

Staubach P, Metz M, Chapman‐Rothe N, et al. Omalizumab rapidly improves angioedema‐related quality of life in adult patients with chronic spontaneous urticaria: X‐ACT study data. Allergy. 2018;73(3):576‐584. PubMed PMC

Spekhorst LS, van den Reek J, Knulst AC, Rockmann H. Determinants of omalizumab drug survival in a long‐term daily practice cohort of patients with chronic urticaria. Allergy 2018. (in press). PubMed

Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA 2016;315(5):469‐479. PubMed

Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol. 2017;140(4):1024‐1031.e14. PubMed

Bidder T, Sahota J, Rennie C, Lund VJ, Robinson DS, Kariyawasam HH. Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together‐a real life study. Rhinology. 2018;56(1):42‐45. PubMed

Tsetsos N, Goudakos JK, Daskalakis D, Konstantinidis I, Markou K. Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review. Rhinology. 2018;56(1):11‐21. PubMed

Fokkens WJ, Bachert C, Bernal‐Sprekelsen M, et al. Rhinology future debates, an EUFOREA report. Rhinology. 2017;55(4):298‐304. PubMed

Hellings PW, Akdis CA, Bachert C, et al. EUFOREA rhinology research forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis. Rhinology. 2017;55(3):202‐210. PubMed

Dudvarski Z, Djukic V, Janosevic L, Tomanovic N, Soldatovic I. Influence of asthma on quality of life and clinical characteristics of patients with nasal polyposis. Eur Arch Otorhinolaryngology 2013;270(4):1379‐1383. PubMed

Sahlstrand‐Johnson P, Hopkins C, Ohlsson B, Ahlner‐Elmqvist M. The effect of endoscopic sinus surgery on quality of life and absenteeism in patients with chronic rhinosinuitis ‐ a multi‐centre study. Rhinology. 2017;55(3):251‐261. PubMed

Smith KA, Orlandi RR, Rudmik L. Cost of adult chronic rhinosinusitis: a systematic review. Laryngoscope. 2015;125(7):1547‐1556. PubMed

Croy I, Nordin S, Hummel T. Olfactory disorders and quality of life–an updated review. Chem Senses 2014;39(3):185‐194. PubMed

Hummel T, Whitcroft KL, Andrews P, et al. Position paper on olfactory dysfunction. Rhinol Suppl. 2017;54:1-30. PubMed

Toma S, Hopkins C. Stratification of SNOT‐22 scores into mild, moderate or severe and relationship with other subjective instruments. Rhinology. 2016;54(2):129‐133. PubMed

Hellings PW, Fokkens WJ, Akdis C, et al. Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? Allergy. 2013;68(1):1‐7. PubMed

van der Veen J, Seys SF, Timmermans M, et al. Real‐life study showing uncontrolled rhinosinusitis after sinus surgery in a tertiary referral centre. Allergy. 2017;72(2):282‐290. PubMed PMC

Winblad L, Larsen CG, Hakansson K, Abrahamsen B, von Buchwald C. The risk of osteoporosis in oral steroid treatment for nasal polyposis: a systematic review. Rhinology. 2017;55(3):195‐201. PubMed

DeConde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith TL. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127(3):550‐555. PubMed PMC

Hopkins C, Slack R, Lund V, Brown P, Copley L, Browne J. Long‐term outcomes from the English national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis. Laryngoscope. 2009;119(12):2459‐2465. PubMed

Vlaminck S, Vauterin T, Hellings PW, et al. The importance of local eosinophilia in the surgical outcome of chronic rhinosinusitis: a 3‐year prospective observational study. Am J Rhinol Allergy. 2014;28(3):260‐264. PubMed

Wei B, Liu F, Zhang J, et al. Multivariate analysis of inflammatory endotypes in recurrent nasal polyposis in a Chinese population. Rhinology. 2018;56(3):216‐226. PubMed

Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343‐373. PubMed

Schlosser RJ, Smith TL, Mace J, Soler ZM. Asthma quality of life and control after sinus surgery in patients with chronic rhinosinusitis. Allergy. 2017;72(3):483‐491. PubMed PMC

Phillips KM, Bergmark RW, Hoehle LP, Caradonna DS, Gray ST, Sedaghat AR. Chronic rhinosinusitis exacerbations are differentially associated with lost productivity based on asthma status. Rhinology. 2018;56(4):323‐329. PubMed

Phillips KM, Hoehle LP, Bergmark RW, et al. Chronic rhinosinusitis severity is associated with need for asthma‐related systemic corticosteroids. Rhinology. 2017;55(3):211‐217. PubMed

Solèr M, Matz J, Townley R, et al. The anti‐IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2):254‐261. PubMed

Magnan A, Bourdin A, Prazma CM, et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. Allergy. 2016;71(9):1335‐1344. PubMed PMC

Pepper AN, Renz H, Casale TB, Garn H. Biologic therapy and novel molecular targets of severe asthma. J Allergy Clin Immunol Pract. 2017;5(4):909‐916. PubMed

Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis. J Allergy Clin Immunol. 2015;136(6):1431‐1440. PubMed

Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110‐6.e1. PubMed

Bachert C, Zhang N, Hellings PW, Bousquet J. Endotype‐driven care pathways in patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2018;141(5):1543‐1551. PubMed

Hellings PW, Fokkens WJ, Bachert C, et al. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis ‐ A EUFOREA‐ARIA‐EPOS‐AIRWAYS ICP statement. Allergy. 2017;72(9):1297‐1305. PubMed

Hopkins C, Rimmer J, Lund VJ. Does time to endoscopic sinus surgery impact outcomes in chronic rhinosinusitis? Prospective findings from the national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis. Rhinology. 2015;53(1):10‐17. PubMed

New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis

Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma

Real-life assessment of chronic rhinosinusitis patients using mobile technology: The mySinusitisCoach project by EUFOREA